### Variant Information for rs121913529
The variant **rs121913529** is located in the **KRAS** gene, which encodes a small GTPase involved in cell signaling pathways that regulate cell proliferation, differentiation, and survival. This variant is associated with multiple molecular mechanisms due to its role in altering the KRAS protein's function.

---

### 1. **Variant Identification**
- **Gene**: KRAS
- **HGVS Notations**:
  - **c.35G>T** (p.Gly12Val)
  - **c.35G>C** (p.Gly12Ala)
  - **c.35G>A** (p.Gly12Asp)
- **Transcript**: ENST00000256078.10
- **dbSNP Link**: [rs121913529](https://identifiers.org/dbsnp/rs121913529)
- **TogoVar Link**: [TogoVar rs121913529](https://togovar.org/variant/rs121913529)

---

### 2. **Molecular Mechanisms Affected**
The rs121913529 variant affects the **KRAS protein's GTPase activity**, leading to constitutive activation of downstream signaling pathways. Below are the key molecular mechanisms:

#### a. **Constitutive Activation of KRAS**
- The variant results in amino acid substitutions at position 12 (Glycine to Valine, Alanine, or Aspartic acid). Glycine 12 is located in the GTP-binding domain of KRAS, which is critical for its ability to hydrolyze GTP to GDP.
- These substitutions impair GTP hydrolysis, locking KRAS in its active GTP-bound state. This leads to **persistent activation of downstream signaling pathways**, such as:
  - **MAPK/ERK pathway**: Promotes cell proliferation.
  - **PI3K/AKT pathway**: Enhances cell survival and growth.

#### b. **Oncogenic Transformation**
- The constitutively active KRAS protein drives **uncontrolled cell division**, contributing to oncogenesis. This is a hallmark of many cancers, including lung, colorectal, and pancreatic cancers.

#### c. **Resistance to Apoptosis**
- The variant enhances anti-apoptotic signaling through the PI3K/AKT pathway, making cells resistant to programmed cell death.

#### d. **Altered Cellular Metabolism**
- KRAS mutations are known to reprogram cellular metabolism to support rapid cell growth, including increased glucose uptake and glycolysis (Warburg effect).

#### e. **Impact on Tumor Microenvironment**
- Mutant KRAS can influence the tumor microenvironment by promoting angiogenesis and immune evasion.

---

### 3. **Disease Associations**
The rs121913529 variant is associated with several cancers and syndromes:
- **Non-small cell lung carcinoma (NSCLC)**
- **Colorectal cancer**
- **Pancreatic cancer**
- **RASopathies** (e.g., Linear nevus sebaceous syndrome)

---

### 4. **Predictive Models**
- **SIFT**: 0.0 (deleterious)
- **PolyPhen-2**: 0.985 (probably damaging for p.Gly12Val)
- **AlphaMissense**: 0.9949 (high pathogenicity)

---

### 5. **Allele Frequency**
- **Global Frequency**: Rare (e.g., 6.8e-07 in gnomAD exomes for c.35G>T).

---

### Summary
The rs121913529 variant in the KRAS gene disrupts normal GTPase activity, leading to constitutive activation of KRAS and downstream signaling pathways. This drives oncogenesis, resistance to apoptosis, and altered cellular metabolism, contributing to the development and progression of various cancers.

---

### 日本語での説明
**rs121913529**は、細胞増殖や分化、生存を制御するシグナル伝達経路に関与する**KRAS遺伝子**に位置する変異です。この変異はKRASタンパク質の機能を変化させ、以下の分子メカニズムに影響を与えます。

#### 1. **KRASの恒常的活性化**
- KRASタンパク質の12番目のグリシン（Glycine）がバリン（Valine）、アラニン（Alanine）、またはアスパラギン酸（Aspartic acid）に置換されます。
- この変化により、KRASはGTPをGDPに加水分解する能力を失い、**活性型（GTP結合型）**の状態が持続します。
- これにより、以下のシグナル経路が恒常的に活性化されます：
  - **MAPK/ERK経路**：細胞増殖を促進。
  - **PI3K/AKT経路**：細胞の生存と成長を強化。

#### 2. **がん化の促進**
- 恒常的に活性化されたKRASは、**制御不能な細胞分裂**を引き起こし、がんの発生に寄与します。

#### 3. **アポトーシス抵抗性**
- PI3K/AKT経路を介して抗アポトーシスシグナルが強化され、細胞がプログラムされた細胞死に抵抗します。

#### 4. **代謝の変化**
- KRAS変異は、細胞の代謝を再プログラムし、急速な細胞成長を支えるためにグルコース取り込みと解糖系を増加させます（ワールブルク効果）。

#### 5. **疾患との関連**
- **非小細胞肺がん**
- **大腸がん**
- **膵臓がん**
- **RASopathy**（例：線状脂腺母斑症候群）

この変異は、がんの進行や治療抵抗性に重要な役割を果たします。

---

**参考リンク**:
- [dbSNP rs121913529](https://identifiers.org/dbsnp/rs121913529)
- [TogoVar rs121913529](https://togovar.org/variant/rs121913529)